Path to first patient dosing
Highlights:
Patients being screened for eligibility, with first-patient dosing expected in October — a major milestone for Arovella
Arovella Therapeutics Ltd (ASX: ALA) advises that screening is underway to identify patients for its phase 1 ALA-101 study. First patient dosing is now expected to occur towards the end of October 2026.
The first-in-human trial will evaluate ALA-101 in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and leukaemia. Potential participants are first identified by their treating clinicians based on their diagnosis and medical history, then provided with information about the study and asked to give informed consent before trial-specific screening begins. Screening involves a detailed assessment against the protocol’s eligibility criteria, including clinical examinations and laboratory tests. Patients undergo this process at The Alfred Hospital, with enrolment dependent on confirmation that all eligibility criteria and clinical requirements have been met. If a patient does not pass screening for any reason, or decides not to participate, they cannot be enrolled and the identification, consent and screening process must begin again. Since there is only a single dosing slot available at the beginning of the trial, patients are screened one at a time for ethical reasons.
The revised dosing timetable is not a reflection of patient availability or demand for the study. Instead, it reflects the practical requirements associated with meeting the strict eligibility requirements in a first-in-human cellular therapy trial.
Acting Chief Executive Officer, Dr Nicole van der Weerden, said, "The level of interest from clinicians and patients in the ALA-101 study is exciting. However, identifying patients who meet all eligibility criteria and completing the screening process is prescribed and takes time. There is no shortage of patients requiring treatment and we have everything in place to dose the first patient once eligibility is confirmed."